Retraction notice to “Curcumin restores Nrf2 levels and prevents quinolinic acid-induced neurotoxicity “ (Journal of Nutritional Biochemistry (2013) 24 (14–24)(S0955286312000332)(10.1016/j.jnutbio.2011.12.010));Curcumin restores Nrf2 levels and prevents quinolinic acid-induced neurotoxicity

Journal of Nutritional Biochemistry

Volumn 24, Issue 1, 2013, Pages 14-24

  Carmona Ramírez, Iván ^a   Santamaría, Abel ^a   Tobón Velasco, Julio C ^a,b   Orozco Ibarra, Marisol ^a   González Herrera, Irma G ^a   Pedraza Chaverrí, José ^b   Maldonado, Perla D ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b Universidad Nacional Autonoma de Mexico Facultad de Quimica   (Mexico)

Author keywords

Curcumin; Nrf2; Oxidative stress; Quinolinic acid

Indexed keywords

CARBONYL DERIVATIVE; CURCUMIN; GLUTATHIONE PEROXIDASE; QUINOLINIC ACID; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; MORPHOLOGY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; RAT; ROTATION;

ANIMALIA; RATTUS;

EID: 84870460559     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2017.03.001     Document Type: Erratum

References (57)

1. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262:689-695.
2. Santamaria A., Jimenez M.E. Oxidative/nitrosative stress, a common factor in different neurotoxic paradigms: an overview. Curr Topics Neurochem Res Trends 2005, 4:1-20.
3. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 1999, 59:427-468.
4. Cowan C.M., Raymond L.A. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 2006, 75:25-71.
5. Nakamura K., Animoff M.J. Huntington's disease: clinical characteristics, pathogenesis and therapies. Drugs Today (Barc) 2007, 43:97-116.
6. Olney J.W., Adamo N.J., Ratner A. Monosodium glutamate effects. Science 1971, 172:294.
7. Schwarcz R., Scholz D., Coyle J.T. Structure-activity relations for the neurotoxicity of kainic acid derivatives and glutamate analogues. Neuropharmacology 1978, 17:145-151.
8. Nicholls D.G., Johnson-Cadwell L., Vesce S., Jekabsons M., Yadava N. Bioenergetics of mitochondria in cultured neurons and their role in glutamate excitotoxicity. J Neurosci Res 2007, 85:3206-3212.
9. Beal M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 2004, 36:381-386.
10. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
11. Sas K., Robotka H., Toldi J., Vécsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007, 257:221-239.
12. Chen Y., Guillemin G.J. Kynurenine pathway metabolites in humans: Disease and Healthy states. Int J Tryptophan Res 2009, 2:1-19.
13. Pérez-De La Cruz V., Königsberg M., Santamaría A. Kynurenine pathway and disease: an overview. CNS Neurol Disord Drug Targets 2007, 6:398-410.
14. McLin J.P., Thompson L.M., Steward O. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. Eur J Neurosci 2006, 24:3134-3140.
15. Santamaría A., Salvatierra-Sánchez R., Vázquez-Román B., Santiago-López D., Villeda-Hernández J., Galván-Arzate S., et al. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. J Neurochem 2003, 86:479-488.
16. Santamaría A., Jiménez-Capdeville M.E., Camacho A., Rodríguez-Martínez E., Flores A., Galván-Arzate S. In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport 2001, 12:2693-2696.
17. Rodríguez-Martínez E., Camacho A., Maldonado P.D., Pedraza-Chaverrí J., Santamaría D., Galván-Arzate S., et al. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res 2000, 858:436-439.
18. Pérez-De La Cruz V., González-Cortés C., Galván-Arzate S., Medina-Campos O.N., Pérez-Severiano F., Ali S.F., et al. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrinate iron (III). Neuroscience 2005, 135:463-474.
19. Behan W.M., McDonald M., Darlington L.G., Stone T.W. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 1999, 128:1754-1760.
20. Silva-Adaya D., Pérez-De La Cruz V., Herrera-Mundo M.N., Mendoza-Macedo K., Villeda-Hernández J., Binienda Z., et al. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine. J Neurochem 2008, 105:677-689.
21. Braidy N., Grant R., Adams S., Guillemin G.J. Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J 2010, 277:368-382.
22. Al-Omar F.A., Nagi M.N., Abdulgadir M.M., Al-Joni K.S., Al-Majed A.A. Immediate and delayed treatments with curcumin prevents forebrain ischemia-induced neuronal damage and oxidative insult in the rat hippocampus. Neurochem Res 2006, 31:611-618.
23. Yang C., Zhang X., Fan H., Liu Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res 2009, 1282:133-141.
24. Pan R., Qiu S., DX L.U., Dong J. Curcumin improves learning and memory ability and its neuroprotective mechanism in mice. Chin Med J 2008, 121:832-839.
25. Ataie A., Sabetkasaie M., Haghparast A., Hajizadeh Moghaddam A., Kazeminejad B. Neuroprotective effects of the polyphenolic antioxidant agent, Curcumin, against homocysteine-induced cognitive impairment and oxidative stress in the rat. Pharmacol Biochem Behav 2010, 96:378-385.
26. Blumenthal M., Goldberg A., Brinkman J. Herbal Medicine: the expanded commission E monographs 2000, 330-334. Integrative Medicine Communications, Newton MA.
27. Begum A.N., Jones M.R., Lim G.P., Morihara T., Kim P., Heath D.D., et al. Curcumine structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008, 326:196-208.
28. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005, 280:5892-5901.
29. Agrawal R., Mishra B., Tyagi E., Nath C., Shukla R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res 2010, 61:247-252.
30. Dairam A., Fogel R., Daya S., Limson J.L. Antioxidant and iron-binding properties of curcumin, capsaicin, and S-allylcysteine reduce oxidative stress in rat brain homogenate. J Agric Food Chem 2008, 56:3350-3356.
31. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, London, UK. 4th ed.
32. Maldonado P.D., Molina-Jijón E., Villeda-Hernández J., Gálvan-Arzate S., Santamaría A., Pedraza-Chaverrí J. NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic/prooxidant model of Huntington's disease in rats: protective role of apocynin. J Neurosci Res 2010, 88:620-629.
33. Silva-Adaya D., Pérez-De La Cruz V., Villeda-Hernández J., Carrillo-Mora P., González-Herrera I.G., García E., et al. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol 2011, 33:303-312.
34. Schmued L.C., Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 2000, 874:123-130.
35. Espada S., Ortega F., Molina-Jijón E., Rojo A.I., Pérez-Sen R., Pedraza-Chaverri J., et al. The purinergic P2Y(13) receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. Free Radic Biol Med 2010, 49(3):416-426.
36. Hamanaka R.B., Chandel N.S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. TiBS 2010, 35:505-513.
37. Santamaría A., Ríos C. MK-801, an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci Lett 1993, 159:51-54.
38. Aguilera P., Chánez-Cárdenas M.E., Floriano-Sánchez E., Barrera D., Santamaría A., Sánchez-González D.J., et al. Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease. Neurotoxicology 2007, 28:1200-1207.
39. Maldonado P.D., Chánez-Cárdenas M.E., Barrera D., Villeda-Hernández J., Santamaría A., Pedraza-Chaverrí J. Poly(ADP-ribose) polymerase-1 is involved in the neuronal death induced by quinolinic acid in rats. Neurosci Lett 2007, 425:28-33.
40. Pérez-De La Cruz V., Konigsberg M., Pedraza-Chaverri J., Herrera-Mundo N., Díaz-Muñoz M., Morán J., et al. Cytoplasmic calcium mediates oxidative damage in an excitotoxic /energetic deficit synergic model in rats. Eur J Neurosci 2008, 27:1075-1085.
41. Sayre L.M., Perry G., Smith M.A. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008, 21:172-188.
42. Dalle-Donne I., Rossi R., Giustarini D., Milzani A., Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003, 329:23-38.
43. Norman A.B., Wyatt L.M., Hildebrand J.P., Kolmonpunporn M., Moody C.A., Lehman M.N., et al. Sensitization of rotation behavior in rats with unilateral 6-hydroxydopamine or kainic acid-induced striatal lesions. Pharmacol Biochem Behav 1990, 37:755-759.
44. Santamaría A., Ríos C., Solís-Hernández F., Ordaz-Moreno J., González-Reynoso L., Altagracia M., et al. Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology 1996, 35:23-28.
45. Dong X.X., Wang Y., Qin Z.H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009, 30:379-387.
46. Lee M.C., Ting K.K., Adams S., Brew B.J., Chung R., Guillemin G.J. Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One 2010, 5:e14123.
47. Jellinger K.A. Recent advances in our understanding of neurodegeneration. J Neural Transm 2009, 116:1111-1162.
48. Ramsey C.P., Glass C.A., Montgomery M.B., Lindl K.A., Ritson G.P., Chia L.A., et al. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007, 66:75-85.
49. Gao X., Dinkova-Kostova A.T., Talalay P. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc Natl Acad Sci U S A 2001, 98:15221-15226.
50. Moosmann B., Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs 2002, 11:1407-1435.
51. Fatokun A.A., Stone T.W., Smith R.A. Oxidative stress in neurodegeneration and available means of protection. Front Biosci 2008, 13:3288-3311.
52. Moi P., Chan K., Asunis I., Cao A., Kan Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 1994, 91:9926-9930.
53. Lee J.M., Calkins M.J., Chan K., Kan Y.W., Johnson J.A. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003, 278:12029-12038.
54. Balogun E., Hoque M., Gong P., Killeen E., Green C.J., Foresti R., et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 2003, 371:887-895.
55. Nishinaka T., Ichijo Y., Ito M., Kimura M., Katsuyama M., Iwata K., et al. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol Lett 2007, 170:238-247.
56. Dinkova-Kostova A.T., Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis 1999, 20:911-914.
57. Hu C., Eggler A.L., Mesecar A.D., van Breemen R.B. Modification of keap1 cysteine residues by sulforaphane. Chem Res Toxicol 2011, 24:515-521.